Your browser doesn't support javascript.
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
Koehler, Johanna; Ritzer, Barbara; Weidlich, Simon; Gebhardt, Friedemann; Kirchhoff, Chlodwig; Gempt, Jens; Querbach, Christiane; Hoffmann, Dieter; Haller, Bernhard; Schmid, Roland M; Schneider, Jochen; Spinner, Christoph D; Iakoubov, Roman.
  • Koehler J; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Ritzer B; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Weidlich S; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Gebhardt F; School of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany.
  • Kirchhoff C; Department of Traumatology, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Gempt J; Department of Neurosurgery, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Querbach C; School of Medicine, Hospital Pharmacy, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Hoffmann D; School of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.
  • Haller B; Institute of Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany.
  • Schmid RM; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Schneider J; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Spinner CD; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Iakoubov R; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany. roman.iakoubov@mri.tum.de.
Infection ; 49(6): 1313-1318, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1303394
ABSTRACT
Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Infection / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Infection Year: 2021 Document Type: Article Affiliation country: S15010-021-01657-y

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Infection / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Infection Year: 2021 Document Type: Article Affiliation country: S15010-021-01657-y